A panoramic, practice-based view of intravenous alteplase 3-4.5 h after stroke.
Kasner
Scott E
SE
Levine
Steven R
SR
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous / Q000379:methods; D010781:Photography; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator